Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selinexor and Reduced-Dose Radiotherapy in Early-Stage ENKTCL
NCT07554482Phase 2Not yet recruiting
- Sponsor
- Beijing Tongren Hospital
- Start
- May 2026
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of selinexor in Extranodal NK/T-cell lymphoma (ENKTL), sponsored by Beijing Tongren Hospital. Planned start May 2026; status: not yet recruiting.
02
Drugs
selinexor
03
Conditions
Extranodal NK/T-cell lymphoma (ENKTL)
Beyond the preview
Go deeper on NCT07554482.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07554482.